Investigational drug · Phase 2
ES102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ES102"
First trial start
2025
Apr 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ES102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ES102" as an intervention, largest first.
- A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid TumorsCompleted
Elpiscience Biopharma, Ltd.Industry
NCT04991506 · 30 participants · Start Oct 15, 2021 · Primary completion May 17, 2024
Drug: ES102; JS001 · For: Solid Tumor; Neoplasms; Malignant Tumor
Sites: Changchun, China
- A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung CancerActive, not recruiting
Elpiscience (Suzhou) Biopharma, Ltd.Industry
NCT06623136 · 30 participants · Start Apr 30, 2025 · Primary completion Feb 28, 2027
Drug: ES102; Toripalimab · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Zhengzhou, China; Nanchang, China · 9 sites in all
Elpiscience Biopharma, Ltd.Industry
NCT04730843 · 18 participants · Start Apr 1, 2021 · Primary completion Mar 1, 2024
Drug: ES102 · For: Solid Tumors; Neoplasms; Malignant Tumor
Sites: Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
- Characterization ofantifungal properties of lipopeptide-producing Bacillus velezensis strains and their proteome-based response to the phytopathogens, Diaporthe spp.
Akintayo SO, Hosseini B, Vahidinasab M, et al. · Front Bioeng Biotechnol 2023
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.